Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486107 | 1.00 | ITGB3 (0.56) | ITGB3ITGA2BITGB1ITGA4MAPK1 | |
| SCHEMBL1907653 | 0.89 | ITGB3 (0.53) | ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL2320402 | 0.89 | FPR2 (0.54) | ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL8485515 | 0.89 | FPR2 (0.54) | ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL10638413 | 0.88 | ITGB3 (0.67) | ITGB3ITGA2B | |
| SCHEMBL14485365 | 0.88 | ITGB3 (0.54) | ITGB3ITGA2BITGB1ITGA4GAA | |
| SCHEMBL5085763 | 0.87 | ITGB1 (0.56) | ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL5086266 | 0.87 | ITGB1 (0.56) | ITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL2252894 | 0.87 | FOLH1 (0.56) | ITGB3ITGA2BITGB1ITGA4MAPK1 | |
| SCHEMBL2252892 | 0.87 | FOLH1 (0.56) | ITGB3ITGA2BITGB1ITGA4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| EP-2870137-B1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-05-16 | — | — | EP | disclosed |
| US-9512065-B2 | Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-12-06 | — | — | US | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150191421-A1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-07-09 | — | — | US | disclosed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2870137-A1 | POLYMORPHS OF N-[(R)-1 -[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOY L]-2-(4-E THOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | Kalvista Pharmaceuticals Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| EP-2729443-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| WO-2014006414-A1 | POLYMORPHS OF|N-[(R)-1 -[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOY L]-2-(4-E|THOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013005045-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191421-A1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | SCN1A, SCN1B, BBC3 | ITGB3 1449/4885ITGA2B 962/4885ITGB1 940/4885 |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | ITGB3 2699/4885ITGA2B 2921/4885ITGB1 2359/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | ITGB3 2699/4885ITGA2B 2921/4885ITGB1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.